All In Biotech

Drug Trial Radar · NCT07846358

This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

A Phase Ib/II, Multicenter, Open-Label Study To Evaluate Safety, Efficacy And Pharmacokinetics Of GFH276 In Combination With Tislelizumab, Pemetrexed And Platinum (Carboplatin Or Cisplatin) As First-Line Therapy In Participants With Locally Advanced Or Metastatic Non-Squamous Non-Small-Cell Lung Cancer Harboring RAS Mutation

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) harboring RAS mutation or KRAS amplification.

Conditions

  • RAS Mutation
  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • GFH276Drug

    Oral GFH276, administered at specified dose on schedule.

  • with or without TislelizumabDrug

    Tislelizumab 200 mg, intravenous infusion, once every 3 weeks.or without Tislelizumab

  • PemetrexedDrug

    Pemetrexed 500 mg/m², intravenous infusion, once every 3 weeks.

  • CisplatinDrug

    Cisplatin 75 mg/m², intravenous infusion, once every 3 weeks.

  • CarboplatinDrug

    Carboplatin at AUC=5, intravenous infusion, once every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib:Incidence of Dose-Limiting Toxicity (DLT) EventsTime frame: First 21 days
  2. Phase II:Objective Response Rate (ORR)Time frame: From the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
  3. Phase Ib:Incidence and Severity of Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: From the first dose until 30 days after the last dose, assessed up to 36 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.